Market Newsdesk

HERZLIYA, Israel, Dec. 31, 2020 (GLOBE NEWSWIRE) — Safe-T® Group Ltd. (NASDAQ, TASE: SFET), a provider of secure access solutions for on-premise and hybrid cloud environments, today announced the launch by its subsidiary, NetNut Ltd., of a new free consumer VPN application that will be available on all operating systems.

The new product, which will offer secure access in over 100 countries across the world, is based on the global presence of NetNut’s residential network and is expected to generate substantial user streams shortly after launch.

The new VPN application allows users to enjoy a high-quality, secured internet access experience, which up until now was available only for paying users in the VPN consumer market.

“We are excited about launching this new product today and expect it to contribute to our performance in the short term. The new VPN application helped drive our decision to enter the proxy market and will ultimately lead to increasing synergies between our defense cybersecurity unit and our proxy unit. Additionally, we are planning to expand the use of the new product in the future as a basis for new enterprise and consumer products,” said Shachar Daniel, CEO of Safe-T Group.

“We believe that the combination of a strong VPN application with our superior access network will result in one of the best products in the VPN consumer market. We are happy to offer it as a free service for end users and are also working on integrating it with Safe-T’s security solution for enterprises as part of the ZoneZero™ offering,” added Barak Avitbul, CEO of NetNut Ltd.

About Safe-T®

Safe-T Group Ltd. (Nasdaq, TASE: SFET) is a provider of access solutions which mitigate attacks on enterprises’ business-critical services and sensitive data, while ensuring uninterrupted business continuity. Safe-T’s cloud and on-premises solutions ensure that an organization’s access use cases, whether into the organization or from the organization out to the internet, are secured according to the “validate first, access later” philosophy of zero trust. This means that no one is trusted by default from inside or outside the network, and verification is required from everyone trying to gain access to resources on the network or in the cloud.

Safe-T’s wide range of access solutions reduce organizations’ attack surface and improve their ability to defend against modern cyberthreats. As an additional layer of security, our integrated business-grade global proxy solution cloud service enables smooth and efficient traffic flow, interruption-free service, unlimited concurrent connections, instant scaling and simple integration with our services. With Safe-T’s patented reverse-access technology and proprietary routing technology, organizations of all size and type can secure their data, services and networks against internal and external threats. At Safe-T, we empower enterprises to safely migrate to the cloud and enable digital transformation.

For more information about Safe-T, visit www.safe-t.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, Safe-T is using forward-looking statements in this press release when it discusses the potential benefits, potential synergies and impact on future product development of the new VPN application and the expectation that it will contribute to Safe-T’s performance in the short term. Because such statements deal with future events and are based on Safe-T’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Safe-T could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Safe-T’s annual report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on March 31, 2020, and in any subsequent filings with the SEC. Except as otherwise required by law, Safe-T undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Safe-T is not responsible for the contents of third-party websites.

INVESTOR RELATIONS CONTACT

Gary Guyton
MZ Group – MZ North America
469-778-7844
[email protected]
www.mzgroup.us

Michal Efraty
+972-(0)52-3044404
[email protected]

COMPANY CONTACT

Maya Meiri
[email protected]
+972-9-8666110

BILLERICA, Mass., Dec. 31, 2020 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ: CFMS), a leader in patient-specific knee and hip instrumentation and implants, announced today that Mark Augusti, Chief Executive Officer, and Bob Howe, Chief Financial Officer, will participate in two virtual investor conferences in January 2021.

39

^th

Annual JP Morgan Healthcare Conference

• The 39^th Annual JP Morgan Healthcare Conference will take place virtually January 11-14, 2021. CFMS management will present on Thursday, January 14 from 7:30 a.m. (4:30 a.m. PT) until 8:10 a.m. ET, including a Q & A session.
• Conformis management will also be available for one-on-one meetings throughout the conference. For more information about the conference or to schedule a one-on-one meeting with management, please contact your JP Morgan representative or contact Investor Relations at [email protected] and (781) 374-5598.

H.C. Wainwright Bioconnect 2021 Conference

• The H.C. Wainwright Bioconnect 2021 Conference will take place virtually January 11-14, 2021. CFMS management will provide a pre-recorded presentation which will be available to registered investors on demand via the conference website.
• Conformis management will also be available for one-on-one meetings throughout the conference. For more information about the conference or to schedule a one-on-one meeting with management, please contact your H.C. Wainwright representative or contact Investor Relations at [email protected] and (781) 374-5598.

About Conformis, Inc.

Conformis is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which we refer to as personalized, individualized, or sometimes as customized, to fit and conform to each patient’s unique anatomy.  Conformis offers a broad line of sterile, personalized knee and hip implants and single-use instruments delivered to hospitals.

In clinical studies, the Conformis iTotal CR knee replacement system demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints. For more information, visit www.comformis.com. To receive future releases in e-mail alerts, sign up at http://ir.conformis.com.

Investor Contact:
[email protected]
(781) 374-5598

• Skylight Health is a US healthcare services and technology company providing multi-disciplinary care to over 135,000 patients across 15 states
• In 2020, the Company announced 5 new clinical acquisitions representing 4 new US markets, over 50,000 new patients and adds aggregate annualized revenue of approximately $13 million and EBITDA of $2.5 million
• The Company has validated its model of strategic clinical acquisitions at 3-7x EBITDA with aggressive plans for organic growth through existing primary care and sub-specialty services
• Over 2020, the Company completed 3 financings including 2 bought deals raising over $22 million with participation from over 11 institutions in Canada and the United States.
• The Company exits 2020 with no long-term debt and strong cash balance to execute towards a robust and growing acquisition pipeline.
• Skylight Health Received Conditional Approval of TSX Venture Listing and expects to commence trading in early January 2021 under the symbol “SHG.V”.
• In the US, the Company began trading under the new OTCQX Ticker “SHGFF” in December, upgrading from the OTCQB. 

TORONTO, Dec. 31, 2020 (GLOBE NEWSWIRE) — Skylight Health Group Inc (CSE:SHG; OTCQX:SHGFF) (“SHG” or the “Company”), one of the largest multi-specialty healthcare systems in the United States, is pleased to provide shareholders with a 12-month overview of accelerating revenue and profitability in 2020.

The US healthcare market represents a multi-trillion-dollar opportunity ripe for disruption. Skylight has a hybrid approach to healthcare delivery. In-clinic services to support patient needs where standards of care require the physical presence of a health care provider; and virtual telemedicine to support patients who may not need to travel or further expose themselves by receiving the same quality of care from the comfort of their home. With a multi-disciplinary approach, the Company brings primary care, sub-specialty, allied health & wellness and laboratory/diagnostic services under one roof.

Skylight operates an organic growth strategy on the back of a growth-by acquisition model. Acquisitions are attractively priced between 3 to 7 times EBITDA or in some cases, less than 1 times revenue. The Company has already demonstrated its ability to target, qualify and acquire with over 5 transactions in the last 60 days. At any given time, there are more than 200 potential acquisition opportunities in the market throughout the US that are seen as an ideal addition to Skylight Health. The Company believes this pathway to growth will continue to result in growth opportunities that are accretive to its core clinical offerings and add immediate revenue and positive EBITDA.

Incremental to each acquisition, the Company employs a proven multi-disciplinary platform backed by 25+ years of founder led clinical management expertise, to enhance the existing base of clinical revenue and broaden the offerings available within each clinic. The Company’s clinic network will offer primary care services. Additional services will be based on each population set in each region and will complement the healthcare needs of patients.

The Company also operates a disruptive subscription-based telemedicine offering for un/under-insured patients at US$199/year that enables access to over 40 million Americans who cannot access healthcare due to the high-cost barrier.

As the Company looks forward to 2021, the roadmap will be to execute against its 3-pronged growth model which include growth by way of strategic acquisition, organic growth within each clinical practice and expansion of its subscription-based service.

Prad Sekar, CEO, Skylight Health said “2020 has been nothing short of a transformative year for the Company. Delivering adjusted EBITDA positivity, strengthening of our balance sheet with cash and extinguishing long-term debt, and adding strong revenue and profitability growth as we exit 2020 should make all of us at Skylight and amongst our shareholders and other stakeholders feel proud and excited for the year ahead. We are certainly looking forward to building on this momentum and further strengthening our position in the US market for 2021. We thank all our stakeholders for their continued support. Best wishes and Happy New Year!”

About Skylight Health Group

Skylight Health Group (CSE:SHG; OTCQX:SHGFF) is a healthcare services and technology company, working to positively impact patient health outcomes. The Company operates a US multi-state health network that comprises of physical multi-disciplinary medical clinics providing a range of services from primary care, sub-specialty, allied health and laboratory/diagnostic testing. The Company owns and operates a proprietary electronic health record system that supports the delivery of care to patients via telemedicine and other remote monitoring system integrations. With a patient roster of over 120,000 patients, the Company’s operations servicing 15 states and continues to expand in services and locations both organically and by way of strategic acquisitions.

The Company primarily operates a traditional insurable fee-for-service model contracting with Medicare, Medicaid, and other Commercial Payors. The Company also offers a disruptive subscription-based telemedicine service for the un/under-insured population who have limited access to urgent care due to cost.

For more information, please visit www.skylighthealthgroup.com or contact:

Investor Relations
Jonathan L. Robinson CFA
Oak Hill Financial
[email protected]
416-669-1001

Currency Usage, Cautionary and Forward-Looking Statements

All currency contained in this Press Release represent Canadian Dollars unless otherwise stated.

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Skylight Health’s filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements regarding the Company’s unaudited financial results and projected growth.

Although Skylight Health has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: the ability of Skylight Health to execute on its business strategy, continued revenue growth in accordance with management’s expectations, operating expenses continuing in accordance with management expectations, dependence on obtaining regulatory approvals; Skylight Health being able to find, complete and effectively integrate target acquisitions; change in laws relating to health care regulation; reliance on management; requirements for additional financing; competition; hindering market growth or other factors that may not currently be known by the Company.

There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Skylight Health disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Skylight Health does not assume any liability for disclosure relating to any other company mentioned herein.

Non-GAAP Financial Measures

This Press Release contains references to Adjusted EBITDA and Gross Margin. These financial measures are not measures that have any standardized meaning prescribed by IFRS and are therefore referred to as non-GAAP measures. The non-GAAP measures used by the corporation may not be comparable to similar measures used by other companies. Adjusted EBITDA is defined as “income (loss) before interest expenses, taxes, expenses related to listing on the Canadian Securities Exchange, depreciation, foreign exchange and financial expenses.

The Company uses these non-GAAP measures because they provide additional information on the performance of its commercial operations. Such tools are frequently used in the business world to analyze and compare the performance of businesses; however, the Company’s definition of these metrics may differ from those of other businesses. Skylight Health will, at times, use certain non-GAAP financial measures to provide readers with additional information in order to assist investors in understanding our financial and operating performance.  Skylight Health believes that these non-GAAP measures provide readers with useful information about the Company’s operating results, enhance the overall understanding of past financial performance and future prospects, and allow for greater transparency with respect to key metrics used by management in its financial and operational decision making.

Adjusted EBITDA excludes the effect of share-based compensation expenses and related payroll taxes as well as removes substantial one-time costs for unusual business activities. Additional discussion on this can be found in the Skylight Health Management Discussion and Analysis filed on SEDAR.

Such non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, the corresponding measures calculated in accordance with IFRS. See the Company’s audited Financial Statements for a reconciliation of the non-GAAP measures.

No securities regulator or exchange has reviewed, approved, disapproved, or accepts responsibility for the content of this news release.